AURX Stock — Nuo Therapeutics Inc

Nuo Therapeutics Inc (AURX)

Updated October 15, 2026.

AURX is a Stock. Total return is -35.0% over the past 9.7 years, 319.5 points behind SPY at 284.5%.

Nuo Therapeutics is a regenerative therapies company that develops and commercializes cell-based technologies for chronic wound care, primarily through its Aurix System, which produces platelet-based therapy from patients' own blood. The company serves hospital outpatient wound care clinics and private practice physicians in the United States. Distribution information is not available.

AURX performance versus SPY

Price and return data through 2026-10-15.

Total return is -35.0% over the past 9.7 years, 319.5 points behind SPY at 284.5%. Over the past year its total return — price change plus distributions reinvested — is -45.8%. Its deepest 1-year drawdown was 70.1%.

AURX key facts

Asset type

Stock

Asset class

Equity

Inception date

02/14/2017

Distribution frequency

None

Last close

$1.30 (as of 2026-10-15)

Market cap

$62,963,910

Average volume

27700.0

Payout ratio

0.0%

EPS

$-0.04

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AURX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 70.1%.

Who may consider AURX — and who may not

It is a weaker fit for investors who need monthly cash flow (AURX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AURX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions